Respiratory Syncytial Virus (RSV)

RSV Prevention Guidelines in UAE

Long acting Monoclonal Antibody is now mandatory for all infants in UAE

Real-World Effectiveness of Nirsevimab: Evidence from the NIRSE-GAL Study

The NIRSE-GAL study is an ongoing population-based, prospective, longitudinal study conducted in Galicia, Spain. It includes infants eligible to receive nirsevimab and evaluates its impact on RSV-related outcomes in both inpatient and outpatient healthcare settings.

Epidemiology and Healthcare Burden Attributable to Laboratory-Confirmed RSV Cases Among Children Under Five Years Old in Saudi Arabia

An overview of the latest Saudi evidence presented at ESPID 2026.

Healthcare Resource Utilization and Direct Medical Costs of RSV Infection in Children Under Five Years in Saudi Arabia

An overview of the latest Saudi evidence presented at ESPID 2026.

Expanding RSV Protection in Kuwait: New National Directives for Monoclonal Antibody Use

Summary of Kuwait’s updated RSV prevention policy

Evidence on Nirsevimab: Sustained Impact Across Two RSV Seasons

Drawing on data NirseGAL, this page provides healthcare professionals with evidence-based insights into nirsevimab's sustained protective impact across  two consecutive RSV seasons

Healthcare Utilization and Economic Burden of RSV Infections Among Children Under 5 Years in Saudi Arabia: A MNGHA Facilities Analysis

Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia

Healthcare Utilization and Economic Burden of Pediatric Lower Respiratory Tract Infections Across Five Tertiary Hospitals in Saudi Arabia

Nirsevimab FAQs

RWE data on Nirsevimab and RSV preF vaccine

Real‑world evidence (RWE) provides valuable insights into the effectiveness, safety, and use of RSV preventive strategies beyond clinical trials. This data support informed decision‑making and optimize the implementation of RSV prevention strategies in real‑world settings

Saudi National immunization strategy for RSV prevention

Ensuring overall RSV prevention in every individual Dr. Alia Podcast

Kuwait taking the lead in RSV protection for all infants in the Middle east

Podcast Dr. Dana Hajan

Epidemiological Characteristics of RSV

RSV Burden in Jazan

Beyond High-Risk: Expanding RSV Protection for Newborns and Infants

New horizon of RSV lower respiratory tract disease LRTD in infants: Reflection on two seasons of prevention

Nirsevimab RWD Metanalysis

Nirsevimab Metanalysis Real world data

Real World Evidence Impact of universal immunization with Nirsevimab

Burden of Disease

RSV History

RSV

All Infant Protection

Nirsevimab : Clinical Experience

RSV Burden in Infants

Nirsevimab International Recommendation

Rattle

Saudi initiatives on Bronchiolitis Recommendations

The first choice of RSV prevention is Nirsevimab; alternatively, palivizumab is to be considered in case of unavailability of Nirsevimab.

Implementing Beyfortus successfully (FR)

Implementing Beyfortus successfully (US)

Beyfortus in Action ECMMID

Implementing Beyfortus successfully

Implementing Beyfortus successfully (ES)

Beyfortus in Action

2024 RSV International Congress - ESPID

2024 RSV International Congress ECMMID

Beyfortus®, an innovative immunization